Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Phase 4 | 2026-10-05 | NCT04781140 | |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2026-10-01 | NCT06798896 | |
| Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-07-15 | NCT02736656 | |
| Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy | Epileptic Seizures, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2026-04-21 | NCT05518578 | |
| Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-03-24 | NCT07226661 | |
| National Pregnancy Registry for Psychiatric Medications | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Not stated | 2025-10-24 | NCT01246765 | |
| Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2025-10-22 | NCT07219927 | |
| SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2025-10-10 | NCT07141329 | |
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 1 / Phase 2 | 2022-08-30 | NCT03474770 |